Table 1.
Reactive by PA or ELISA | Indeterminate samples (IS) n (%) | IS Confirmed HTLV-1+ by n-PCR n (%) | IS Confirmed HTLV-2+ by n-PCR n (%) | Total HTLV-1 Prevalence % (n/N) | Total HTLV-2 Prevalence % (n/N) | |
---|---|---|---|---|---|---|
MSM (N=667) | 26 | 11 (1.65) | 3 (27.28) | 0 (0) | 0.45% (3/667) c | 0% (0/667)c |
IDU (N=173) | 36 | 4 (2.31 ) | 4 (100 ) | 2 b (100 ) | 4.62% (8/173) c | 15.6% (27/173) c |
FSW (N=613) | 25 | 3 (2.12) | 3 (23.10 ) | 0 (0 ) | 1.46% (9/613) c | 0.2% (1/613) c |
HDC (N=578) | 207 | 30 (5.19 ) | 3 (15.79) a | 2 (10.53)a | 18.8% (109/578) | 5.36% (31/578) |
Total | 294 | 48 (16.33) | 13 (35.13) | 4 (10.81) | 6.35% (129/2031) | 2.90% (59/2031) |
aOut of 30 seroindeterminate samples, only 19 could be tested by molecular techniques, as no DNA was available for the other 11. bThese two samples were HTLV-1/2 co-infected. cData reported by Berini et al. 2007 [26].